Long-term Tecfidera use was found to significantly reduce relapse rates and slow disability progression for MS patients in a ...

Glucarpidase -- a carboxypeptidase enzyme that helps break down and remove methotrexate from the body -- was approved by the FDA in 2012 to treat patients with toxic levels of methotrexate in their ...

Long COVID prevalence and burden continue to decrease among health care workers however, some still experience everyday life restrictions.

Patients with rheumatoid arthritis (RA) face heightened risks for COVID-19 infection, hospitalization, and mortality, according to results of a systematic review and meta-analysis published in BMC ...

In the world of drug development, the timing and design of clinical trials can be crucial in getting a new drug to market ...

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in natural psilocybin and MDMA, ...

Drs. Flynn, Park, Kovatsis and Jena are physicians and researchers at Harvard Medical School. Dr. Jena is an author of ...

Patients with generalized myasthenia gravis experienced durable improvements across measures of efficacy and regardless of the time since they were diagnosed.

The study highlights a powerful relationship between regular physical activity and a lower risk of chronic diseases.

With holiday gatherings and New Year's celebrations in the rearview mirror, many Americans are coming down with respiratory ...

Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel).

Significant improvements have been made at a Stockton hospice, a new inspection has found, marking an "important milestone" for the "delighted" charity chief. Butterwick Hospice has been upgraded from ...